

Patient NAME	DATE OF BIRTH	DISEASE	STAGE	Physician NAME
Mrs John Doe	1992-Jun-12	Colorectal	II	Administrator
SPECIMEN	VIAL IDs			
20ml Blood	1			

REPORT SUMMARY

The ELISA assay results of the patient, show that there is down-regulation of immunity. According to the ELISA analysis the deactivation of the immunity is based on overproduction of relevant factors like CD25, CTLA4

Information

Laboratory Process

1. Serum isolation from 8ml of whole blood with centrifugation.
2. Specific immunity activation/suppression cytokines were measured by ELISA assay.
3. Flow cytometry run for the requested cell markers directly to whole blood.

The data arising from the two assays were then analyzed and compared to the normal ones. During the test the environmental temperature was: 23o C ± 1o C.

Disclaimers

*This Test Report is issued based on testing the sample / specimen examined by the Laboratory. Modification of data, selective breeding and using portions of this test report is forbidden. The laboratory assumes no liability for improper use or improper interpretation of the result

Immunity Activation / Suppression

CELL TYPE		MARKERS/CYTOKINES	RESULT	OUTCOME
B Cells	Plasma Cells	CD19	0.06	-
B Cells	Naïve B Cells	CD20	4.6	-
B Cells	Memory Cells	CD28	0.96	-
T Cells	CD8 - Cytotoxic T Lymphocytes (CTLs)	CD62L	0.03	-
T Cells	CD4 - Cell Mediated Immunity	IFN- γ (Interferon Gamma)	-3.68	↓
T Cells	CD4 - Humoral Immunity	IL-4 (Interleukin 4)	4.27	↑
		IL-6 (Interleukin 6)	2.36	↑
		IL-2 (Interleukin 2)	-1.48	↓
T Cells	CD4 - Suppressed Immunity	TNF- α	-2.05	↓
		CD25 (T Regulatory Cells)	0.04	-
		CTLA4 (T Regulatory Cells)	0.01	-
T Cells	Memory Cells	CD28	0.27	-
Antigen Presenting Cells	Dendritic Cells (DCs)	CD80	0.01	-
		CD86	0.03	-

Sincerely,

Dr. Ioannis Papatiriu MD, PhD, SCym

- a. Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C. The immune response to tumors as a tool toward immunotherapy. *Clin Dev Immunol*. 2011;2011:894704. doi: 10.1155/2011/894704. Epub 2011 Dec 5. PMID: 22190975; PMCID: PMC3235449.
- b. Yuan W, Cai W, Huang X, Peng S. Prognostic value of immune scores in the microenvironment of colorectal cancer. *Oncol Lett*. 2020 Nov;20(5):256. doi: 10.3892/ol.2020.12119. Epub 2020 Sep 18. PMID: 32994819; PMCID: PMC7509622.
- c. Patel HJ, Patel BM. TNF- α and cancer cachexia: Molecular insights and clinical implications. *Life Sci*. 2017 Feb 1;170:56-63. doi: 10.1016/j.lfs.2016.11.033. Epub 2016 Dec 3. PMID: 27919820.
- d. Kang S, Brown HM, Hwang S. Direct Antiviral Mechanisms of Interferon-Gamma. *Immune Netw*. 2018 Oct 17;18(5):e33. doi: 10.4110/in.2018.18.e33. PMID: 30402328; PMCID: PMC6215902.
- e. Cortes-Selva D, Ready A, Gibbs L, Rajwa B, Fairfax KC. IL-4 promotes stromal cell expansion and is critical for development of a type-2, but not a type 1 immune response. *Eur J Immunol*. 2019 Mar;49(3):428-442. doi: 10.1002/eji.201847789. Epub 2019 Jan 3. PMID: 30575951; PMCID: PMC6953475.
- f. Bendickova K, Fric J. Roles of IL-2 in bridging adaptive and innate immunity, and as a tool for cellular immunotherapy. *J Leukoc Biol*. 2020 Jul;108(1):427-437. doi: 10.1002/JLB.5MIR0420-055R. Epub 2020 Jun 1. PMID: 32480431; PMCID: PMC7384134.
- g. Benihoud K, Salone B, Esselin S, Opolon P, Poli V, Di Giovine M, Perricaudet M, Saggio I. The role of IL-6 in the inflammatory and humoral response to adenoviral vectors. *J Gene Med*. 2000 May-Jun;2(3):194-203. doi: 10.1002/(SICI)1521-2254(200005/06)2:3<194::AID-JGM102>3.0.CO;2-5. PMID: 10894265.
- h. Wu Z, Li S, Zhu X. The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity. *Front Immunol*. 2021 Jun 10;12:682435. doi: 10.3389/fimmu.2021.682435. PMID: 34194437; PMCID: PMC8237941.
- i. Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. *Mol Biol Rep*. 2021 Dec;48(12):8075-8095. doi: 10.1007/s11033-021-06752-9. Epub 2021 Oct 20. PMID: 34671902; PMCID: PMC8605995.